APA (7th ed.) Citation

Jing, X., Li, L., Lu, S., Zhai, X., & Zhu, H. (2026). Remarkable response to Osimertinib plus Gumarontinib for EGFR mutation and concomitant MET exon 14 skipping in a patient with lung adenocarcinoma: A case report. Oncology Letters, 31(1), N.PAG. https://doi.org/10.3892/ol.2025.15385

Chicago Style (17th ed.) Citation

Jing, Xuquan, Li Li, Shuangqing Lu, Xiaoyang Zhai, and Hui Zhu. "Remarkable Response to Osimertinib Plus Gumarontinib for EGFR Mutation and Concomitant MET Exon 14 Skipping in a Patient with Lung Adenocarcinoma: A Case Report." Oncology Letters 31, no. 1 (2026): N.PAG. https://doi.org/10.3892/ol.2025.15385.

MLA (9th ed.) Citation

Jing, Xuquan, et al. "Remarkable Response to Osimertinib Plus Gumarontinib for EGFR Mutation and Concomitant MET Exon 14 Skipping in a Patient with Lung Adenocarcinoma: A Case Report." Oncology Letters, vol. 31, no. 1, 2026, p. N.PAG, https://doi.org/10.3892/ol.2025.15385.